Therapeutic effect of chitosan modification on salmon-calcitonin-loaded PLGA nanoparticles

Lee, Min‐Jeong; Seo, Da-Young; Lee, Hea-Eun; Choi, Guang J.

doi:10.1007/s11814-010-0508-9

Cited by 10 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Once NPs are lyophilized, they are suspended in a CS buffer solution under stirring. Both strategies were assayed by Lee et al (2011) [18] who prepared salmon-calcitonin-loaded PLGA for oral administration. Important differences in particle size between methods were found.…”

Section: Adsorption By Electrostatic Interactionmentioning

confidence: 99%

Functional PLGA NPs for Oral Drug Delivery: Recent Strategies and Developments

Martín-Banderas¹,

Durán‐Lobato²,

Muñoz-Rubio³

et al. 2013

Mini Reviews in Medicinal Chemistry

View full text Add to dashboard Cite

This article presents the potential of PLGA nanoparticles for the oral administration of drugs. Different strategies are used to improve oral absorption of these nanoparticles. These strategies are based on modification of nanoparticle surface properties. They can be achieved either by coating the nanoparticle surface with stabilizing hydrophilic bioadhesive polymers or surfactants, or by incorporating biodegradable copolymers containing a hydrophilic moiety. Some substances such as chitosan, vitamin E, methacrylates, lectins, lecithins, bile salts and RGD molecules are employed for this purpose. Of especial interest are nanoparticles production methods and, in order to improve oral bioavailability, the mechanism of each additive.

show abstract

Section: Adsorption By Electrostatic Interactionmentioning

confidence: 99%

Functional PLGA NPs for Oral Drug Delivery: Recent Strategies and Developments

Martín-Banderas¹,

Durán‐Lobato²,

Muñoz-Rubio³

et al. 2013

Mini Reviews in Medicinal Chemistry

View full text Add to dashboard Cite

show abstract

“…[38] The mucosal adhesive properties of chitosan can increase the diffusion or absorption of drugs by prolonging the time in the stomach. [39] Chitosan was also selected as a ligand for nanoparticles because of its low toxicity, biodegradability, responsiveness to pH and mucosal adhesion, and the chitosan-coated system has been used as an effective oral system for many protein-peptide drugs, non-viral genes, DNA and vaccines. nucleic acids.…”

Section: As Oral L-arginine Delivery Systemmentioning

confidence: 99%

The Potency of Oral L-Arginine Suplementation Based on Chitosan-Coated Gold Nanoparticles (c-AuNPs) as Preeclampsia Prevention in Pregnant Women

Syafira

Deanasa

Afladhanti

2022

SCRIPTA SCORE Sci Med J.

View full text Add to dashboard Cite

Preeclampsia is a multi-systemic hypertensive disorder in pregnant women after two weeks of gestation and can cause complications in about 6-10% of all pregnancies. The incidence of preeclampsia in Indonesia is 128,273/year or about 5.3%. However, the handling of preeclampsia in Indonesia is still not optimal. This disease is difficult to detect and often appears suddenly, so prevention efforts need to be taken as an essential step in reducing morbidity and mortality due to this disease. Previous studies have shown that L-Arginine exhibits potential properties in preventing preeclampsia. This literature review aims to determine the potential for oral L-Arginine supplementation to prevent preeclampsia in pregnant women. Search for literature using search engines such as Google Scholar, Science Direct, ResearchGate, and NCBI. Inclusion and exclusion criteria are used to eliminate unrelated journals so 38 journals are obtained. L-Arginine has great potential as a preventive supplementation of preeclampsia by increasing the vascular NO synthesis where NO deficiency in pregnant women can induce changes in the uteroplacental structure. Supplementation of the dietary L-Arginine at a low dose of 3 g/day for three to four weeks is required in early pregnancy. The use of chitosan-coated gold nanoparticles (c-AuNPs) as encapsulation on a protein increases the bioavailability of oral supplementation and improves the patient's clinical state. Further research regarding the effectiveness of L-Arginine supplementation orally with c-AuNPs and the optimal dosage as a preeclampsia preventive supplement is needed.

show abstract

“…18 Successful utilization of PLGA for delivery of biomolecules has been proven in many researches especially in proteins, nucleic acids and therapeutic medicines. [19][20][21][22][23] Surface modification of NPs was performed to enhance the solubility of this polymer from cells to targeted organs. It is important to select suitable substances to increase susceptibility of PLGA NPs to a specified target.…”

Section: Introductionmentioning

confidence: 99%

Delivery of Grouper Interferon by Chitosan-Modified Poly(lactic-co-glycolic acid) Nanoparticles to Protect Nervous Necrosis Virus Infection

Ping¹,

Ling²,

Wei³

et al. 2016

j nanosci nanotechnol

View full text Add to dashboard Cite

The outbreaks of viral disease including nervous necrosis virus (NNV) have become major problems in aquaculture and cause massive mortalities of grouper larvae, leading to enormous economic losses for farms and hatcheries. Interferons (IFNs) are potent antiviral cytokines that enhance a grouper larva innate immune system by triggering various antiviral proteins. In this study, we utilized ultra-sonication to nano-encapsulate grouper IFN (gIFN) using chitosan modified poly(lactic-coglycolic acid) (PLGA) as a carrier. Sample obtained was expressed as PLGA-gIFN NP expecting to protect IFN from the damage in a fish gastrointestinal tract. The results showed that nanoparticles (NPs) loaded with gIFN were monodisperse with sizes ranged around 150 nm and successfully achieved an acceptable encapsulation efficiency of 65.5%. Particles were stable during storage with an initial burst release in the first 4 h and shown a low cumulative release rate only of 18% which limited an anti-NNV effect of IFN in the animal test. However, with a dosage increasing from 0.05 to 0.1 g of PLGA-gIFN/fish in oral administration, the relative percent survival (RPS) increased by 12.38 to 46.67, that seemed to be better in an increasing rate compare to the non-encapsulated one (RPS rose to 60.59 from 34.07). It is deduced that this nano-encapsulation technique could protect IFNs from damage in a fish gastrointestinal tract and performed its functionality when been uptaken into cells. Since NPs are able to approach easily using sonication, the less cytotoxic PLGAgIFN NPs could be produced commercially as a reliable and promising aquaculture pharmaceutical product for disease prevention and treatment in fish fries.

show abstract

Therapeutic effect of chitosan modification on salmon-calcitonin-loaded PLGA nanoparticles

Cited by 10 publications

References 19 publications

Functional PLGA NPs for Oral Drug Delivery: Recent Strategies and Developments

Functional PLGA NPs for Oral Drug Delivery: Recent Strategies and Developments

The Potency of Oral L-Arginine Suplementation Based on Chitosan-Coated Gold Nanoparticles (c-AuNPs) as Preeclampsia Prevention in Pregnant Women

Delivery of Grouper Interferon by Chitosan-Modified Poly(lactic-co-glycolic acid) Nanoparticles to Protect Nervous Necrosis Virus Infection

Contact Info

Product

Resources

About